Volume 146, Issue 2, Pages (February 2014)

Slides:

Advertisements

Similar presentations

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Advertisements

Volume 149, Issue 6, Pages (November 2015)

Volume 148, Issue 2, Pages e1 (February 2015)

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

Volume 139, Issue 4, Pages (October 2010)

Volume 151, Issue 5, Pages (November 2016)

Christoph Lübbert, Babett Holler Gastroenterology

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Volume 139, Issue 4, Pages (October 2010)

Spontaneous Self-Expulsion of a Large Stone From the Abdomen

Volume 153, Issue 1, Pages e5 (July 2017)

Effectiveness of Hepatitis B Treatment in Clinical Practice

Is HCV Infection a Neurologic Disorder?

Volume 146, Issue 3, Pages e1 (March 2014)

Outcomes Among Living Liver Donors

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

How to Critically Read the GI Epidemiology Literature

Ira J. Fox, Stephen C. Strom Gastroenterology

Volume 149, Issue 4, Pages e1 (October 2015)

Volume 59, Issue 4, Pages (October 2013)

Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection Steven L. Flamm, Eric Lawitz,

Volume 142, Issue 4, Pages (April 2012)

Volume 152, Issue 6, Pages e2 (May 2017)

Volume 151, Issue 4, Pages e1 (October 2016)

Michael Biermer, Thomas Berg Gastroenterology

Covering the Cover Gastroenterology

A Historical Perspective on Clinical Advances in Pancreatic Diseases

Volume 150, Issue 4, Pages (April 2016)

Volume 154, Issue 4, Pages (March 2018)

Volume 155, Issue 5, Pages e2 (November 2018)

Jean-Michel Pawlotsky Gastroenterology

Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial

Volume 156, Issue 3, Pages (February 2019)

Update on the Use of Vonoprazan: A Competitive Acid Blocker

Colon Cancer: An Update and Future Directions

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.

Not Your Ordinary Ulcer: A Cautionary Tale of an Uncommon Condition

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Volume 142, Issue 6, Pages (May 2012)

Laura Rotundo, Sushil Ahlawat Gastroenterology

Volume 141, Issue 1, Pages (July 2011)

Rafael Esteban, Maria Buti Gastroenterology

Melena and Hyperammonemic Seizures in a Turner Syndrome Patient

Volume 145, Issue 4, Pages e3 (October 2013)

Ashwin N. Ananthakrishnan, David Lieberman Gastroenterology

Volume 148, Issue 3, Pages (March 2015)

Genetic Factors and Hepatitis C Virus Infection

Volume 148, Issue 2, Pages e1 (February 2015)

Volume 141, Issue 6, Pages (December 2011)

Volume 150, Issue 7, Pages (June 2016)

Covering the Cover Gastroenterology

The Dawning of a New Editorial Board for Gastroenterology

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Volume 132, Issue 1, Pages (January 2007)

Volume 150, Issue 7, Pages (June 2016)

Risks Associated With Anesthesia Services During Colonoscopy

A “Crescent-in-doughnut” Lesion at Right Lower Quadrant Abdomen

Volume 130, Issue 7, Pages (June 2006)

Volume 155, Issue 6, Pages (December 2018)

Volume 139, Issue 6, Pages e1 (December 2010)

Volume 147, Issue 6, Pages (December 2014)

Volume 138, Issue 6, Pages (May 2010)

Covering the Cover Gastroenterology

Our New President—Anil K. Rustgi, MD

Electronic Clinical Challenges and Images in GI

The Future of Endoscopic Retrograde Cholangiopancreatography

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,

Presentation transcript:

Volume 146, Issue 2, Pages 420-429 (February 2014) Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection Gregory T. Everson, Karen D. Sims, Maribel Rodriguez-Torres, Christophe Hézode, Eric Lawitz, Marc Bourlière, Veronique Loustaud- Ratti, Vinod Rustgi, Howard Schwartz, Harvey Tatum, Patrick Marcellin, Stanislas Pol, Paul J. Thuluvath, Timothy Eley, Xiaodong Wang, Shu-Pang Huang, Fiona McPhee, Megan Wind-Rotolo, Ellen Chung, Claudio Pasquinelli, Dennis M. Grasela, David F. Gardiner Gastroenterology Volume 146, Issue 2, Pages 420-429 (February 2014) DOI: 10.1053/j.gastro.2013.10.057 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 (A-D) HCV-RNA levels over time for individual patients in groups 1-4. Patients were treated with daclatasvir (60 mg, orally, once daily), asunaprevir (200 mg, orally, twice daily), plus (A) BMS-791325 75 mg twice daily for 24 weeks, (B) BMS-791325 75 mg twice daily for 12 weeks, (C) BMS-791325 150 mg twice daily for 24 weeks, (D) or BMS-791325 150 mg twice daily for 12 weeks. N equals 16 each for groups 1 through 3, and 18 for group 4. PT, post-treatment. Gastroenterology 2014 146, 420-429DOI: (10.1053/j.gastro.2013.10.057) Copyright © 2014 AGA Institute Terms and Conditions